Madrigal Pharmaceuticals (MDGL) CEO logs automatic tax-related share sale

Rhea-AI Filing Summary

Madrigal Pharmaceuticals President and CEO William John Sibold reported an automatic sale of company stock related to taxes. On January 26, 2026, 1,577 shares of Madrigal common stock were sold at $492.42 per share. According to the filing, the issuer sold these shares on his behalf solely to cover tax withholding tied to the vesting of restricted stock units, and the sale was not at his discretion. After this transaction, Sibold directly beneficially owned 148,497 shares of Madrigal common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sibold William John

(Last) (First) (Middle)

C/O MADRIGAL PHARMACEUTICALS, INC.

200 BARR HARBOR DRIVE, SUITE 200

(Street)

WEST CONSHOHOCKEN PA 19428

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MADRIGAL PHARMACEUTICALS, INC. [ MDGL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
01/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/26/2026		S(1)		1,577	D	$492.42	148,497	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person.

Remarks:

	/s/ Mardi Dier, as Attorney-in-Fact	01/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Madrigal Pharmaceuticals (MDGL) report for its CEO?

Madrigal Pharmaceuticals reported that President and CEO William John Sibold had 1,577 shares of common stock sold on his behalf on January 26, 2026, as disclosed on a Form 4.

At what price were the Madrigal Pharmaceuticals (MDGL) shares sold in the CEO's Form 4 filing?

The Form 4 shows that 1,577 shares of Madrigal common stock were sold at a price of $492.42 per share.

Why were William John Sibold's Madrigal (MDGL) shares sold in this Form 4 transaction?

The filing explains that the sale represents shares sold by the issuer on behalf of William John Sibold to cover tax withholding obligations related to the vesting of restricted stock units, and that the sale was automatic and not at his discretion.

How many Madrigal Pharmaceuticals (MDGL) shares does the CEO own after this Form 4 sale?

After the reported transaction, President and CEO William John Sibold beneficially owned 148,497 shares of Madrigal Pharmaceuticals common stock directly.

What role does William John Sibold hold at Madrigal Pharmaceuticals (MDGL)?

According to the filing, William John Sibold is both a Director and the President and CEO of Madrigal Pharmaceuticals.

Was the Madrigal (MDGL) CEO’s Form 4 transaction a discretionary sale?

No. The footnote states that the sale was automatic and executed by the issuer to cover tax withholding obligations from restricted stock unit vesting, and was not at the discretion of the reporting person.